These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
817 related items for PubMed ID: 8952541
21. Molecular detection of von Hippel-Lindau gene mutations in urine and lymph node samples in patients with renal cell carcinoma: potential biomarkers for early diagnosis and postoperative metastatic status. Ashida S, Furihata M, Tanimura M, Sugita O, Yamashita M, Miura T, Moriyama M, Shuin T. J Urol; 2003 Jun; 169(6):2089-93. PubMed ID: 12771725 [Abstract] [Full Text] [Related]
22. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Siemeister G, Weindel K, Mohrs K, Barleon B, Martiny-Baron G, Marmé D. Cancer Res; 1996 May 15; 56(10):2299-301. PubMed ID: 8625303 [Abstract] [Full Text] [Related]
23. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Kaelin WG. Clin Cancer Res; 2004 Sep 15; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019 [Abstract] [Full Text] [Related]
24. Genotype-phenotype correlations in families with deletions in the von Hippel-Lindau (VHL) gene. Hes F, Zewald R, Peeters T, Sijmons R, Links T, Verheij J, Matthijs G, Leguis E, Mortier G, van der Torren K, Rosman M, Lips C, Pearson P, van der Luijt R. Hum Genet; 2000 Apr 15; 106(4):425-31. PubMed ID: 10830910 [Abstract] [Full Text] [Related]
25. Von Hippel-Lindau syndrome. A pleomorphic condition. Friedrich CA. Cancer; 1999 Dec 01; 86(11 Suppl):2478-82. PubMed ID: 10630173 [Abstract] [Full Text] [Related]
26. Genotype-phenotype correlation in von Hippel-Lindau syndrome. Friedrich CA. Hum Mol Genet; 2001 Apr 01; 10(7):763-7. PubMed ID: 11257110 [Abstract] [Full Text] [Related]
27. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Foster K, Prowse A, van den Berg A, Fleming S, Hulsbeek MM, Crossey PA, Richards FM, Cairns P, Affara NA, Ferguson-Smith MA. Hum Mol Genet; 1994 Dec 01; 3(12):2169-73. PubMed ID: 7881415 [Abstract] [Full Text] [Related]
35. Von Hippel-Lindau gene alterations in sporadic benign and malignant pheochromocytomas. Dannenberg H, De Krijger RR, van der Harst E, Abbou M, IJzendoorn Y, Komminoth P, Dinjens WN. Int J Cancer; 2003 Jun 10; 105(2):190-5. PubMed ID: 12673678 [Abstract] [Full Text] [Related]
36. The genetic locus NRC-1 within chromosome 3p12 mediates tumor suppression in renal cell carcinoma independently of histological type, tumor microenvironment, and VHL mutation. Lovell M, Lott ST, Wong P, El-Naggar A, Tucker S, Killary AM. Cancer Res; 1999 May 01; 59(9):2182-9. PubMed ID: 10232606 [Abstract] [Full Text] [Related]
37. Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors. Prowse AH, Webster AR, Richards FM, Richard S, Olschwang S, Resche F, Affara NA, Maher ER. Am J Hum Genet; 1997 Apr 01; 60(4):765-71. PubMed ID: 9106522 [Abstract] [Full Text] [Related]
38. VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism. An J, Fisher M, Rettig MB. Oncogene; 2005 Feb 24; 24(9):1563-70. PubMed ID: 15608669 [Abstract] [Full Text] [Related]
39. [Prevention of renal carcinoma: the nutri-genetic approach]. Junien C, Dupret JM, Gallou C, Longuemaux S, Richard S, Saquet C, Krishnamoorty R, Delomenie C, Droz D, Bouvier R, Chauveau D, Joly D, Grunfeld JP, Chretien Y, Mejean A, Beroud C. J Soc Biol; 2000 Feb 24; 194(1):29-38. PubMed ID: 11107547 [Abstract] [Full Text] [Related]